WHO definition of palliative care. World Health Organization website. www.who.int/cancer/palliative/definition/en
Taylor JS, Brown AJ, Prescott LS, Sun CC, Ramondetta LM, Bodurka DC. Dying well: how equal is end of life care among gynecologic oncology patients? Gynecol Oncol. 2016;140(2):295–300.
Buckley de Meritens A, Margolis B, Blinderman C, Prigerson HG, Maciejewski PK, Shen MJ, et al. Practice patterns, attitudes, and barriers to palliative care consultation by gynecologic oncologists. J Oncol Pract. 2017;13(9):e703–11.
Ferrell BR, Temel JS, Temin S, et al. Integration of palliative care into standard oncology care: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2016;35(1):96–112.
Jang TK, Kim SW, Park JY, Suh DS, Kim JH, Kim YM, et al. Trends in treatment during last stages of life in end-stage gynecologic cancer patients who received active palliative chemotherapy: a comparative analysis of 10-year data I a single institution. BMC Palliat Care. 2018;17:99.
Mullen MM, Cripe JC, Thaker PH. Palliative care in gynecologic oncology. Obstet Gynecol Clin North Am. 2019;46:179–97.
Cartoni C, Niscola P, Breccia M, Brunetti G, D’Elia GM, Giovannini M, et al. Hemorrhagic complications in patients with advanced hematological malignancies followed at home: an Italian experience. Leuk Lymphoma. 2009;50(3):387–91.
HES statistics. HES online. Hospital episode statistics:Main procedures and interventions: 4 character. NHS. The information centre for health and social care; 2007-08. http://www.hesonline.nhs.uk/Ease/servlet/ContentServer?siteID=1937&categoryID=215
Pockros PJ, Esrason KT, Nguyen C, Duque J, Woods S. Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics. Gastroenterology. 1992;103(4):1302–6.
Sebastian M. Review of catumaxomab in the treatment of malignant ascites. CMAR. 2010;2:283–6.
Ferriss JS, Java JJ, Bookman MA, Fleming GF, Monk BJ, Walker JL, et al. Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study. Gynecol Oncol. 2015;139(1):17–22.
Sjoquist KM, Espinoza D, Mileshkin L, Ananda S, Shannon C, Yip S, et al. REZOLVE (ANZGOG-1101): a phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer. Gynecol Oncol. 2021;161(2):374–81.
Parshall MB, Schwartzstein RM, Adams L, Banzett RB, Manning HL, Bourbeau J, et al. An official American thoracic society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012;185(4):435–52.
Paul Olson TJ, Pinkerton C, Brasel KJ, Schwarze ML. Palliative surgery for malignant bowel obstruction from carcinomatosis: a systematic review. JAMA Surg. 2014;149(4):383.
Hoppenot C, Peters P, Cowan M, Moore ED, Hurteau J, Lee NK, et al. Malignant bowel obstruction due to uterine or ovarian cancer: are there differences in outcome? Gynecol Oncol. 2019;154(1):177–82.
Rezk Y, Timmins PF, Smith HS. Palliative care in gynecologic oncology. Am J Hosp Palliat Med. 2011;28:356–74.
Landrum LM, Blank S, Chen MLM, Duska L, Bae-jump V, Lee PS, et al. Comprehensive care in gynecology oncology: the importance of palliative care. Gynecol Oncol. 2015;137:193–202.